Whether atropine should be the standard of care for halting myopia progression was a hot topic discussed at the Congress on Controversies in Ophthalmology.

"Most studies on atropine have been carried out in Asian ... of sight-threatening conditions," he noted. Loughman said the ...

The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...